[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20210498A - Composiciones y métodos para tratar el cáncer - Google Patents

Composiciones y métodos para tratar el cáncer

Info

Publication number
CR20210498A
CR20210498A CR20210498A CR20210498A CR20210498A CR 20210498 A CR20210498 A CR 20210498A CR 20210498 A CR20210498 A CR 20210498A CR 20210498 A CR20210498 A CR 20210498A CR 20210498 A CR20210498 A CR 20210498A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
treating cancer
egfr
present disclosure
Prior art date
Application number
CR20210498A
Other languages
English (en)
Inventor
David A Nathanson
Michael E Jung
Peter M Clark
Timothy F Cloughesy
Gyudong Kim
Jonathan Tsang
Lorenz Urner
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CR20210498A publication Critical patent/CR20210498A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se refiere a compuestos que son capaces de penetrar hasta la barrera hematoencefálica para modular la actividad de la tirosina cinasa EGFR. La descripción se refiere además a métodos para tratar el glioblastoma y otros cánceres mediados por EGFR. La descripción se refiere además a métodos para tratar el glioblastoma y otros cánceres mediados por EGFR que se ha determinado que tienen un metabolismo de glucosa alterado en presencia de inhibidores. La presente descripción también proporciona métodos para administrarle a un sujeto un inhibidor del metabolismo de la glucosa y un estabilizador de p53 citoplasmática
CR20210498A 2019-03-15 2020-03-13 Composiciones y métodos para tratar el cáncer CR20210498A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819322P 2019-03-15 2019-03-15
US201962904241P 2019-09-23 2019-09-23
PCT/US2020/022743 WO2020190765A2 (en) 2019-03-15 2020-03-13 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
CR20210498A true CR20210498A (es) 2022-01-11

Family

ID=72521289

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210498A CR20210498A (es) 2019-03-15 2020-03-13 Composiciones y métodos para tratar el cáncer

Country Status (16)

Country Link
US (2) US11377451B2 (es)
EP (1) EP3938354A4 (es)
JP (2) JP7474269B2 (es)
KR (1) KR20210151820A (es)
CN (2) CN113811528A (es)
AU (1) AU2020241703A1 (es)
BR (1) BR112021018295A2 (es)
CA (1) CA3133688A1 (es)
CL (1) CL2021002409A1 (es)
CO (1) CO2021013496A2 (es)
CR (1) CR20210498A (es)
IL (1) IL286350A (es)
MX (1) MX2021011272A (es)
SA (1) SA521430328B1 (es)
SG (1) SG11202109662YA (es)
WO (1) WO2020190765A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
EP3938354A4 (en) 2019-03-15 2022-12-28 The Regents of the University of California CANCER TREATMENT COMPOSITIONS AND METHODS
WO2022061299A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061201A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022155311A1 (en) * 2021-01-14 2022-07-21 The Regents Of The University Of California Methods and systems for analysis of drug target engagement and treatment of cancer
MX2023012060A (es) 2021-04-13 2024-01-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
WO2022240583A1 (en) * 2021-05-12 2022-11-17 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
EP4405360A1 (en) * 2021-09-23 2024-07-31 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors
WO2024081447A1 (en) * 2022-10-14 2024-04-18 The Regents Of The University Of California Egfr inhibitors for treating lung cancer
WO2024102177A1 (en) * 2022-11-08 2024-05-16 The Regents Of The University Of California Combination therapies for the treatment of brain cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
CN1854130B (zh) 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
WO2008046242A1 (fr) 2006-10-16 2008-04-24 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
CN102030742B (zh) 2009-09-28 2013-06-19 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
ITPD20110091A1 (it) 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
KR20200091954A (ko) * 2014-12-15 2020-07-31 더 리젠츠 오브 더 유니버시티 오브 미시간 Egfr 및 pi3k의 소분자 억제제
CN105017163A (zh) 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
US10473255B2 (en) 2015-12-29 2019-11-12 Ge-Hitachi Nuclear Energy Americas Llc Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device
US20190016689A1 (en) 2016-01-06 2019-01-17 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
CN106432202B (zh) 2016-09-22 2019-04-02 郑州大学第一附属医院 喹唑啉类衍生物及其应用
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
EP3938354A4 (en) 2019-03-15 2022-12-28 The Regents of the University of California CANCER TREATMENT COMPOSITIONS AND METHODS
US20240058340A1 (en) 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2022061201A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
EP4405360A1 (en) 2021-09-23 2024-07-31 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
US11377451B2 (en) 2022-07-05
MX2021011272A (es) 2021-10-01
US20220064177A1 (en) 2022-03-03
US20230115366A1 (en) 2023-04-13
JP2024102094A (ja) 2024-07-30
CO2021013496A2 (es) 2022-01-17
WO2020190765A2 (en) 2020-09-24
IL286350A (en) 2021-10-31
BR112021018295A2 (pt) 2021-11-23
CL2021002409A1 (es) 2022-06-17
CN115215808A (zh) 2022-10-21
SG11202109662YA (en) 2021-10-28
JP2022526266A (ja) 2022-05-24
CA3133688A1 (en) 2020-09-24
WO2020190765A3 (en) 2020-11-26
EP3938354A2 (en) 2022-01-19
KR20210151820A (ko) 2021-12-14
CN113811528A (zh) 2021-12-17
AU2020241703A1 (en) 2021-10-14
JP7474269B2 (ja) 2024-04-24
EP3938354A4 (en) 2022-12-28
SA521430328B1 (ar) 2024-03-28

Similar Documents

Publication Publication Date Title
SA521430328B1 (ar) تركيبات وطرق لعلاج السرطان
AU2018368731A8 (en) Combination therapies
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
EA201290139A1 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
EA201290138A1 (ru) Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция
MX363188B (es) Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2010005300A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
WO2009137543A3 (en) Methods for breast cancer screening and treatment
MX2024008551A (es) Terapias de combinacion.
MX2018001507A (es) Composiciones y metodos para tratar cánceres asociados con la activacion del etbr.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
AU2018271862A1 (en) Combination therapy
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
MX2024000674A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2022010860A (es) Terapia combinada que comprende inhibidores de axl/mer y pd-1/pd-l1.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
SG10201609131YA (en) Zinc-pga compositions and methods for treating cancer
WO2009073139A3 (en) Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.